Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
Dr. Reddy’s Laboratories has released its unaudited consolidated financial results for the quarter and nine months ending December 31, 2024. The company reported a revenue of 83,586 million Indian Rupees for the quarter, marking an increase from the previous quarter and year. Gross profit also saw a rise, reaching 49,052 million Indian Rupees. These financial outcomes demonstrate a positive trajectory in the company’s performance, which could enhance its competitive positioning in the global pharmaceutical industry. The financial results underscore the company’s operational efficiency and potential for stakeholder benefits.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical company headquartered in Hyderabad, India. It is involved in the development, manufacture, and marketing of a wide range of pharmaceuticals, including generic medications, active pharmaceutical ingredients (APIs), and proprietary products, serving markets globally with a focus on affordability and accessibility.
YTD Price Performance: -9.70%
Average Trading Volume: 1,485,577
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.44B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
